General anesthesia versus conscious sedation for radial endobronchial ultrasound
Official title: A Randomized Controlled Trial of gEneral aneStheSia vs consciOUs Sedation in Radial endobronChial Ultrasound for Peripheral Pulmonary lEsions
Run by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · NCT06950515 · Data updated 2026-11-12
This trial will see if general anesthesia or conscious sedation gives better diagnostic results for adults undergoing radial endobronchial ultrasound to sample peripheral lung nodules.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 306 (estimated) |
| Sponsor | Institut universitaire de cardiologie et de pneumologie de Québec, University Laval Academic / other |
| Locations | 4 sites (Québec, Quebec and 3 other locations) |
| Status | Recruiting |
| Started | September 25, 2025 |
| Main results expected | August 2027 |
| Study ends | August 2029 |
| Registry record updated | November 9, 2026 |
| Trial ID | NCT06950515 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with a peripheral lung lesion under 5 cm that an interventional pulmonologist judges accessible by pEBUS and who agree to have pEBUS as their diagnostic procedure are ideal candidates.
✕Probably not a fit
Patients who need electromagnetic navigation, augmented fluoroscopy, robotic bronchoscopy, have suspicious lymph nodes requiring separate EBUS-TBNA, or have contraindications to bronchoscopy are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, multicenter trial comparing diagnostic yield of peripheral radial endobronchial ultrasound (pEBUS) performed under general anesthesia versus conscious sedation. Adults with peripheral lung lesions deemed accessible by experienced interventional pulmonologists are randomized to one of the two sedation strategies and undergo pEBUS with standard sampling techniques. Patient comfort questionnaires are collected before discharge and final pathology and procedure outcomes are reviewed from the medical record about one month after the procedure. Key exclusions include planned use of electromagnetic navigation/robotic bronchoscopy, suspicious mediastinal lymph nodes requiring EBUS-TBNA, or contraindications to bronchoscopy.
Why it matters
Potential benefit: If successful, the trial could identify the sedation approach that yields more accurate diagnoses and improves patient comfort during pEBUS.
How similar studies have gone: Previous comparisons of sedation strategies for pEBUS are limited and have not shown a clear, consistent advantage for general anesthesia, so direct evidence is inconclusive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years and ability to consent * Peripheral lung lesion less than 5cm in average diameter on axial CT images (A lung lesion will be considered peripheral if it is located beyond the origin of the subsegmental bronchi and presumed not to be visible endoscopically in white light during the evaluation of the CT scan by an interventional pulmonologist.) * Lesion deemed accessible by pEBUS by an experienced interventional pulmonologist * Decision by the medical team and the patient to use pEBUS as a diagnostic modality for the lung lesion Exclusion Criteria: * Presence of multiple lung lesions with sampling of more than one lung lesion planned * Planned use of electromagnetic navigation, augmented fluoroscopy or robotic bronchoscopy in addition to pEBUS. The use of virtual bronchoscopy planning is permitted * Presence of suspicious lymph nodes (size ≥ 10mm and/or moderate or greater hypermetabolism) on imaging which are accessible by l-EBUS and for which rapid on-site cytological analysis will be used * Contraindication to bronchoscopy or biopsies such as an unstable medical condition or uncorrected coagulopathy * Current pregnancy or lactation * Lack of free and informed consent
Where it's running
-
Institut universitaire de cardiologie et de pneumologie de Québec
Québec, Quebec, Canada Recruiting -
Sotiria Thoracic Diseases Hospital of Athens
Athens, Greece Recruiting -
St. Elisabethen Hospital Frankfurt
Frankfurt am Main, Hesse, Germany Not yet recruiting -
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spain Not yet recruiting
Study contacts
- Study coordinator: Marc Fortin, MD
- Email: marc.fortin@criucpq.ulaval.ca
- Phone: 418-656-8711
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Intraoperative 3D Longitude-Latitude-Depth Localization vs CT-Guided Lung Localization for Small Peripheral Nodules
This study tests whether intraoperative 3D longitude–latitude–depth localization can identify 0.8–2 cm peripheral lung nodules as reliably as the standard preoperative CT-guided localization in adults undergoing VATS surgery.
-
Shape-sensing robotic bronchoscopy to diagnose peripheral lung nodules
This tests a shape-sensing robotic bronchoscopy to see if it can get tissue samples from adults in Korea with peripheral lung nodules.
-
AVZO-1418 alone and with other treatments for advanced epithelial solid tumors
This trial will test whether intravenous AVZO-1418, alone or with other cancer drugs, is safe and helps adults with locally advanced or metastatic epithelial solid tumors, including some lung cancers.
-
Robotic-assisted bronchoscopy versus ultrathin bronchoscopy with virtual navigation for diagnosing peripheral lung nodules
This trial will test whether robotic-assisted bronchoscopy works as well as ultrathin bronchoscopy with virtual bronchoscopic navigation to diagnose peripheral lung nodules in adults who need a non-surgical biopsy.
-
Online and in-person exercise programs for cancer survivors in Canada
This study is testing whether online and in-person exercise programs can help cancer survivors in Canada stay active and improve their health.
-
Super1 TCR-T for NY-ESO-1–positive advanced solid tumors
This trial tests whether a single infusion of Super1 TCR-T can help people with advanced sarcoma, lung cancer, or melanoma whose tumors are HLA-A*02 positive and express NY-ESO-1.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.